– UK, London – ValiRx Plc (LON: VAL) today announced the appointment of Dr Suzanne Dilly to its Board of Directors as CEO effective immediately.
Dr Kevin Cox will be appointed as Non-Executive Chairman, following completion of normal regulatory due diligence to be completed in the coming weeks.
ValiRx is a biotechnology oncology-focused company specialising in developing novel treatments for cancer.
The Company’s business model focuses on identifying and in-licensing early-stage projects, adding value through scientific development and then out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the Company reduces risk while increasing the potential for realising value.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible.
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For more information: https://www.valirx.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.